Journal of Thoracic Oncology (JTO), the official journal of the International Association for
the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection,
diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews
and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists,
radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal
is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment
of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance
to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification
and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker
targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest.
Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic
science studies must have direct clinical and translational relevance.
https://www.mea.elsevierhealth.com/journal-of-thoracic-oncology-15560864.html109845Journal of Thoracic Oncologyhttps://www.mea.elsevierhealth.com/media/catalog/product/1/5/15560864_34.jpg00USDOutOfStock/Revues28526128204 <P>
<B>About the Journal</B>
<P>
<IT>Journal of Thoracic Oncology</IT> (JTO), the official journal of the International Association for
the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection,
diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews
and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists,
radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology. The journal
is interested in receiving manuscripts dealing with epidemiology, prevention, screening, early detection, staging, cure, and treatment
of thoracic malignancies. Submissions on tobacco control and cessation are of interest, particularly where there is direct relevance
to lung cancer epidemiology and therapeutic outcomes. The Journal also welcomes submissions on pathologic and histologic classification
and novel imaging and bronchoscopic approaches. Submissions regarding novel systemic therapies, particularly in the fields of biomarker
targets, genomics, immunology, and cellular therapies are of interest. Novel radiotherapy and surgical techniques are of interest.
Submission of randomized phase II and phase III trials, as well as meta analyses of individual participant data, are encouraged. Basic
science studies must have direct clinical and translational relevance.
USD001556-0864JOURNALELSEVIERIN STOCK1556-0864Volume 14journalsJournalsNoNoNoNoPlease SelectPlease SelectPlease Select